Research
Wegovy Reduces BMI in Kids With Obesity as Young as 6
The Brief
- Results from the phase III STEP Young trial show children ages 6 to 11 with obesity lost significant weight on semaglutide (Wegovy).
- The results were presented at ObesityWeek in National Harbor, Md.
- Reported results are from the trial at week 68, measuring mean change in body mass index (BMI).
Why it matters
It provides trial evidence on a GLP-1 medication for obesity in children as young as 6, an age group with limited drug-trial data.
Who’s affected
- clinicians treating children with obesity
- parents of young children with obesity
(MedPage Today) -- NATIONAL HARBOR, Md. -- Young children ages 6 to 11 years with obesity lost significant weight with the GLP-1 medication semaglutide (Wegovy), according to results from the phase III STEP Young trial. At week 68, mean body...